Aspergillus galactomannan detection and evaluation based on automated system

doi:10.3877/cma.j.issn.2095-5820.2022.03.002

Abstract

Abstract:

Objective

The automated detection system was applied to the detection of Aspergillus galactomannan (GM), and its application value in large-scale clinical laboratories was discussed.

Methods

A total of 66 serum samples, 54 bronchoalveolar lavage fluid (BALF) samples and 15 college of American Pathologists (CAP) PT samples were collected. All samples were tested by automatic microbiology analyzer DNK-A600 and the Bio-Rad Platelia? Aspergillus Ag kit for manual operation for the detection of GM, and the results were compared for consistency.

Results

The total coincidence rate of the two assays was 95.00% among the 120 samples, and the Kappa value was 0.90. The intra-batch and inter-batch precision of DNK-A600 system for GM detection were in line with the industry standard, and the CV value was lower than 15%, and the accuracy coincidence rate was 100%. The verification of the detection limits and cut-off value were all in line with the experimental requirements.

Conclusions

The results of GM detection based on DNK-A600 automatic combined microbial detection system are accurate and reliable, which could realize mutual recognition of GM results with traditional manual detection.

Key words: Galactomannan, GM test, Fully automatic microbial detection system

Yong Liu, Wenqiang Dang, Yuan Zhang, Lei Zhang. Aspergillus galactomannan detection and evaluation based on automated system[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2022, 10(03): 132-136.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2022.03.002

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2022/V10/I03/132

Figures/Tables 5

References 30

1	Zhou LH, Jiang YK, Li RY, et al. Risk-Based Estimate of Human Fungal Disease Burden, China[J]. Emerg Infect Dis, 2020, 26(9): 2137-2147.
2	徐媛, 陈敏, 廖万清. 中国侵袭性曲霉菌病流行病学现状[J]. 中国真菌学杂志, 2018, 13(1): 57-60.
3	夏云, 杜丽, 何云燕. 侵袭性曲霉病实验室诊断的现状和展望[J]. 中华检验医学杂志, 2018, 41(1): 9-12.
4	中国医师协会血液科医师分会, 中国侵袭性真菌感染工作组. 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第六次修订版)[J]. 中华内科杂志, 2020, 59(10): 754-763.
5	Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline[J]. Clin Microbiol Infect, 2018, 24 Suppl 1: e1-e38.
6	中国医药教育协会真菌病专业委员会, 国家皮肤与免疫疾病临床医学研究中心(北京大学第一医院), 国家血液疾病临床医学研究中心(北京大学人民医院). 侵袭性真菌病实验室诊断方法临床应用专家共识[J]. 中华内科杂志, 2022, 61(2): 134-141.
7	Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America [J]. Clin Infect Dis, 2016, 63(4): e1-e60.
8	Miller JM, Binnicker MJ, Campbell S, et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology[J]. Clin Infect Dis, 2018, 67(6): 813-816.
9	胡华, 杨燕, 滕隔玲, 等. 支气管肺泡灌洗液半乳甘露聚糖抗原检测在肺曲霉病诊断中的价值[J]. 中华医学杂志, 2012, 92(32): 2268-2270.
10	孙于谦, 纪宇, 许兰平, 等. 荧光定量聚合酶链反应与血清半乳甘露聚糖检测在侵袭性曲霉病诊断中的价值[J]. 中华医学杂志, 2010, 90(6): 375-378.
11	林鹏程, 曾家豪, 苏珊珊, 等. 半乳甘露聚糖试验诊断重症与危重症流感合并侵袭性肺曲霉病的效能分析[J]. 中华医学杂志, 2021, 101(15): 1050-1056.
12	余进, 李若瑜, 高露娟, 等. 血清半乳甘露聚糖和血浆(1,3)β-D-葡聚糖检测诊断侵袭性真菌感染[J]. 中华医学杂志, 2010, 90(6): 371-374.
13	刘亚迪, 朱骏, 杨一宁, 等. GM抗原检测对血液病患者侵袭性曲霉病的诊断价值[J]. 现代生物医学进展, 2014, 14(32): 6315-6320.
14	施毅, 赵江南. 侵袭性真菌病病原学非培养实验室诊断方法[J]. 中华结核和呼吸杂志, 2019, 42(7): 500-505.
15	Haydour Q, Hage CA, Carmona EM, et al. Diagnosis of Fungal Infections. A Systematic Review and Meta-Analysis Supporting American Thoracic Society Practice Guideline[J]. Ann Am Thorac Soc, 2019, 16(9): 1179-1188.
16	Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis[J]. Clin Infect Dis, 2006, 42(10): 1417-1427.
17	Tong T, Shen J, Xu Y. Serum galactomannan for diagnosing invasive aspergillosis in pediatric patients: A meta-analysis[J]. Microb Pathog, 2018, 118: 347-356.
18	Heng SC, Morrissey O, Chen SC, et al. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis[J]. Crit Rev Microbiol, 2015, 41(1): 124-134.
19	White PL, Price JS, Posso R, et al. An evaluation of the performance of the IMMY aspergillus galactomannan enzyme-linked immunosorbent assay when testing serum to aid in the diagnosis of invasive aspergillosis[J]. J Clin Microbiol, 2020, 58(12).
20	Serin I, Dogu MH. Serum Aspergillus galactomannan lateral flow assay for the diagnosis of invasive aspergillosis: A single-centre study[J]. Mycoses, 2021, 64(6): 678-683.
21	Boch T, Spiess B, Cornely OA, et al. Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-beta-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study[J]. Clin Microbiol Infect, 2016, 22(10): 862-868.
22	Cao XJ, Li YP, Xie LM, et al. Diagnostic Accuracy of Bronchoalveolar Lavage Fluid Galactomannan for Invasive Aspergillosis[J]. Biomed Res Int, 2020, 2020: 5434589.
23	Desai R, Ross LA, Hoffman JA. The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis[J]. Pediatr Infect Dis J, 2009, 28(4): 283-286.
24	Desai R, Ross LA, Hoffman JA. The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis[J]. Pediatr Infect Dis J, 2009, 28(4): 283-286.
25	Pasqualotto AC, Xavier MO, Sanchez LB, et al. Diagnosis of invasive aspergillosis in lung transplant recipients by detection of galactomannan in the bronchoalveolar lavage fluid[J]. Transplantation, 2010, 90(3): 306-311.
26	Kovanda LL, Desai AV, Hope WW. Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis[J]. J Pharmacokinet Pharmacodyn, 2017, 44(2): 143-151.
27	苏铎华, 汤春梅, 邝浩斌, 等. 支气管肺泡灌洗液GM试验对慢性肺曲霉病的早期诊断及疗效评估价值[J]. 临床肺科杂志, 2020, 25(8): 1140-1144.
28	姚佳峰. 侵袭性曲霉病患者动态监测血清半乳甘露聚糖的临床价值研究[D]. 北京: 清华大学医学部、中国医学科学院、北京协和医学院, 2009.
29	Yoshimura K, Suzuki Y, Inoue Y, et al. Utility of serum Aspergillus-galactomannan antigen to evaluate the risk of severe acute exacerbation in chronic obstructive pulmonary disease [J]. PLoS One, 2018, 13(6): e0198479.
30	Arastehfar A, Wickes B L, Ilkit M, et al. Identification of mycoses in developing countries[J]. J Fungi (Basel), 2019, 5(4):90.

项目	例数	阳性符合率［%（95% CI）］	阴性符合率［%（95% CI）］	总符合率［%（95% CI）］	Kappa值
血清	66	97.1（85.47~99.49）	100.0（88.97~100.00）	98.48（91.90~99.73）	0.97
BALF	54	89.2（72.80~96.29）	92.3（75.86~97.86）	90.74（80.09~95.98）	0.81
血清+BALF	120	93.6（84.78~97.50）	96.4（88.08~99.03）	95.00（89.52~97.69）	0.90

项目	例数	阳性符合率［%（95% CI）］	阴性符合率［%（95% CI）］	总符合率［%（95% CI）］	Kappa值
血清	66	97.1（85.47~99.49）	100.0（88.97~100.00）	98.48（91.90~99.73）	0.97
BALF	54	89.2（72.80~96.29）	92.3（75.86~97.86）	90.74（80.09~95.98）	0.81
血清+BALF	120	93.6（84.78~97.50）	96.4（88.08~99.03）	95.00（89.52~97.69）	0.90

检测结果	Bio-Rad	DNK-A600	偏倚（%）
阳性	2.0851	2.1487	3.05
阴性	0.0950	0.1332	40.21
总计	1.421733	1.476867	3.88

检测结果	Bio-Rad	DNK-A600	偏倚（%）
阳性	2.0851	2.1487	3.05
阴性	0.0950	0.1332	40.21
总计	1.421733	1.476867	3.88

样本编号	Ⅰ值	样本编号	I值
1	0.558	11	0.625
2	0.610	12	0.628
3	0.630	13	0.612
4	0.649	14	0.523
5	0.641	15	0.517
6	0.637	16	0.507
7	0.575	17	0.533
8	0.513	18	0.566
9	0.570	19	0.603
10	0.575	20	0.537

Please choose a citation manager

Content to export